Pliant Therapeutics Announces Strategic Realignment of Workforce and Operations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 01 2025
0mins
Source: Globenewswire
Workforce Reduction and Cost-Saving Measures: Pliant Therapeutics is implementing a strategic restructuring that includes a workforce reduction of approximately 45% to extend its cash runway for late-stage clinical trials, particularly the BEACON-IPF trial for idiopathic pulmonary fibrosis (IPF).
Upcoming Data Release: The company expects to release topline data from the BEACON-IPF trial in the second quarter of 2025, which will inform future steps in the development of their lead product candidate, bexotegrast.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
